“…In an effort to search pharmacophore having TSPO selective binding potential (BP) over central benzodiazepine receptor (CBR), several structure‐activity relationship (SAR) analyses have been done in the past (Barresi et al, 2021; Singh et al, 2022). Sailing through these studies the most established the initial pharmacophore that have come up in frontline were 4‐phenylquinazoline‐2‐carboxamides, pyrazolopyrimidines, tricyclic‐indoles, N , N ‐dialkyl‐2‐phenylindol‐3‐ylglyoxylamide (PIGA), N ‐ sec ‐butyl‐4‐(2‐chlorophenyl)‐Nmethylquinazoline‐2‐carboxamide and benzoxazolone (Castellano et al, 2012, 2014; Fukaya et al, 2013; Ikawa et al, 2017; F. Li et al, 2016; O'Shea et al, 2013; Pike et al, 2011; Siméon et al, 2021; Tang et al, 2013; Wadsworth et al, 2012; Zanotti‐Fregonara et al, 2014). The foremost PET ligands representative of these pharmacophore were ( R )[ 11 C]PK11195, [ 11 C]DPA713/[ 11 C]DPA714, [ 18 F]GE‐180, FGIN‐1, and [ 18 F]FEBMP, respectively.…”